-
MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas
Study
EGAS00001004544
-
A Multifactorial Tumor and Immune Cell Profile Determines Response to Immune Checkpoint blockade in Melanoma
Study
EGAS00001004548
-
Super enhancers define regulatory subtypes and cell identity in neuroblastoma - RNA-seq
Study
EGAS00001004552
-
Clinical Outcomes by Tumor Mutational Burden and Inflammatory Gene Expression With Combined Nivolumab and Ipilimumab or Monotherapy in Advanced Melanoma - CM67 WES
Study
EGAS00001004555
-
Regulatory T cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors
Study
EGAS00001004694
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma
Study
EGAS00001004558
-
RNASeq of PDX and CDX tumours treated with ADC
Study
EGAS00001004562
-
Clinical Outcomes by Tumor Mutational Burden and Inflammatory Gene Expression With Combined Nivolumab and Ipilimumab or Monotherapy in Advanced Melanoma
Study
EGAS00001004564
-
Clinical Outcomes by Tumor Mutational Burden and Inflammatory Gene Expression With Combined Nivolumab and Ipilimumab or Monotherapy in Advanced Melanoma - CM066-WES
Study
EGAS00001004567
-
Single cell RNA sequencing of CD19 CAR T-cell infusion products
Study
EGAS00001004576